Scholarlink

Purpose <p>Evidence of the efficacy of neoadjuvant chemotherapy (NAC) for adenocarcinoma of the esophagogastric junction (AEG) in Japanese patients remains limited. This study evaluated the outcomes and prognostic factors for patients with locally advanced Siewert type I/II tumors treated with NAC followed by surgery.</p> Methods <p>The subjects of this retrospective analysis were 101 patients with Siewert type I/II cancer, who underwent NAC followed by surgery. The NAC regimens included S-1 plus cisplatin, S-1 plus oxaliplatin, and fluorouracil, leucovorin, oxaliplatin, and docetaxel. Progression-free survival and prognostic factors were assessed using Kaplan–Meier and Cox regression analyses.</p> Results <p>R0 resection was achieved in 93.1% of the patients, with a Grade ≥ 2 pathological response observed in 31.7%. Significant pathological downstaging was observed in both tumor and nodal stage. The 3-year progression-free survival rate was 59.5%. Multivariable analysis identified Siewert type I tumors (HR: 2.04, 95% CI: 1.10–3.79), pathological T3–4 tumors (HR: 2.93, 95% CI: 1.03–8.39), and incomplete resection (HR: 3.31, 95% CI: 1.35–8.08) as independently associated with poorer prognosis.</p> Conclusion <p>NAC followed by surgery was effective for locally advanced AEG in Japanese patients, yielding high R0 resection rates and favorable survival outcomes. However, Siewert type I tumors, residual pathological T3–4 disease, and incomplete resection remained adverse prognostic factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes and prognostic factors for patients with Siewert type I/II esophagogastric junction adenocarcinoma following neoadjuvant chemotherapy and surgery: a Japanese cohort study

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Masayoshi Terayama,
  • Akihiko Okamura,
  • Tomoyuki Irino,
  • Kaoru Nakano,
  • Naoki Takahashi,
  • Jun Kanamori,
  • Yu Imamura,
  • Masaru Hayami,
  • Motonari Ri,
  • Souya Nunobe,
  • Masayuki Watanabe

摘要

Purpose

Evidence of the efficacy of neoadjuvant chemotherapy (NAC) for adenocarcinoma of the esophagogastric junction (AEG) in Japanese patients remains limited. This study evaluated the outcomes and prognostic factors for patients with locally advanced Siewert type I/II tumors treated with NAC followed by surgery.

Methods

The subjects of this retrospective analysis were 101 patients with Siewert type I/II cancer, who underwent NAC followed by surgery. The NAC regimens included S-1 plus cisplatin, S-1 plus oxaliplatin, and fluorouracil, leucovorin, oxaliplatin, and docetaxel. Progression-free survival and prognostic factors were assessed using Kaplan–Meier and Cox regression analyses.

Results

R0 resection was achieved in 93.1% of the patients, with a Grade ≥ 2 pathological response observed in 31.7%. Significant pathological downstaging was observed in both tumor and nodal stage. The 3-year progression-free survival rate was 59.5%. Multivariable analysis identified Siewert type I tumors (HR: 2.04, 95% CI: 1.10–3.79), pathological T3–4 tumors (HR: 2.93, 95% CI: 1.03–8.39), and incomplete resection (HR: 3.31, 95% CI: 1.35–8.08) as independently associated with poorer prognosis.

Conclusion

NAC followed by surgery was effective for locally advanced AEG in Japanese patients, yielding high R0 resection rates and favorable survival outcomes. However, Siewert type I tumors, residual pathological T3–4 disease, and incomplete resection remained adverse prognostic factors.